BR0013065A - Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos - Google Patents

Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos

Info

Publication number
BR0013065A
BR0013065A BR0013065-6A BR0013065A BR0013065A BR 0013065 A BR0013065 A BR 0013065A BR 0013065 A BR0013065 A BR 0013065A BR 0013065 A BR0013065 A BR 0013065A
Authority
BR
Brazil
Prior art keywords
disease associated
compound
treat
activation
aberrant leukocyte
Prior art date
Application number
BR0013065-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Jay R Luly
Yoshisuke Nakasato
Etsuo Ohshima
Hiroki Sone
Osamu Kotera
Geraldine C B Harriman
Kenneth G Carson
Original Assignee
Millennium Pharm Inc
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc, Kyowa Hakko Kogyo Kk filed Critical Millennium Pharm Inc
Publication of BR0013065A publication Critical patent/BR0013065A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
BR0013065-6A 1999-07-28 2000-07-28 Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos BR0013065A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/362,837 US6509346B2 (en) 1998-01-21 1999-07-28 Chemokine receptor antagonists and methods of use therefor
PCT/US2000/020732 WO2001009138A2 (en) 1999-07-28 2000-07-28 Chemokine receptor antagonists and methods of use therefor

Publications (1)

Publication Number Publication Date
BR0013065A true BR0013065A (pt) 2002-07-30

Family

ID=23427735

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013065-6A BR0013065A (pt) 1999-07-28 2000-07-28 Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos

Country Status (17)

Country Link
US (2) US6509346B2 (https=)
EP (1) EP1204665B1 (https=)
JP (1) JP4903333B2 (https=)
KR (1) KR20020016926A (https=)
CN (1) CN1471536A (https=)
AT (1) ATE420090T1 (https=)
AU (1) AU6391400A (https=)
BR (1) BR0013065A (https=)
CA (1) CA2391267A1 (https=)
DE (1) DE60041336D1 (https=)
EA (1) EA200200194A1 (https=)
ES (1) ES2321798T3 (https=)
HK (1) HK1044333A1 (https=)
HU (1) HUP0202202A3 (https=)
IL (1) IL147852A0 (https=)
MX (1) MXPA02000978A (https=)
WO (1) WO2001009138A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
HU228314B1 (hu) * 1998-09-04 2013-03-28 Millennium Pharmaceuticals Kemokin receptor antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
US6919313B2 (en) * 2001-03-30 2005-07-19 President & Fellows Of Harvard College Protein waving a PDZ and a RGS domain
CN1911930A (zh) * 2001-11-21 2007-02-14 千禧药品公司 趋化因子受体拮抗剂及其方法和用途
US7541365B2 (en) * 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP1553098A1 (en) * 2002-10-18 2005-07-13 Ono Pharmaceutical Co., Ltd. Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
ES2665464T3 (es) * 2003-03-28 2018-04-25 Sigmoid Pharma Limited Forma de dosificación oral sólida que contiene microcápsulas sin costuras
MY140489A (en) * 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
CN100526301C (zh) * 2003-12-26 2009-08-12 卫材R&D管理有限公司 1,2-二(环式基)取代苯化合物
US7410971B2 (en) * 2003-12-26 2008-08-12 Eisai R&D Management Co., Ltd. 1,2-di(cyclic)substituted benzene compounds
US20060276465A1 (en) * 2003-12-26 2006-12-07 Eisai R&D Management Co., Ltd. 1,2-di(cyclic) substituted benzene compounds
DE102004004719A1 (de) * 2004-01-29 2005-08-18 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Aminoalkoholen
EP1802287A2 (en) * 2004-09-27 2007-07-04 Sigmoid Biotechnologies Limited Minicapsule formulations
US7960549B2 (en) * 2004-12-17 2011-06-14 Carole Neves Solid forms of a chemokine receptor antagonist and methods of use thereof
CN101068798B (zh) 2004-12-20 2010-05-12 卫材R&D管理有限公司 1-环丙基甲基-4-[2-(3,3,5,5-四甲基环己基)苯基]哌嗪的盐及结晶
MY144974A (en) * 2005-06-14 2011-11-30 Eisai R&D Man Co Ltd 1,2-di(cyclic) substituted benzene derivatives
ES2393814T3 (es) 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
CA2685118C (en) * 2007-04-26 2016-11-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2008132712A2 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Combination pharmaceutical compositions
US20090286823A1 (en) * 2007-12-17 2009-11-19 Millennium Pharmaceuticals Inc. CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
CN102573802A (zh) 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
WO2011137331A2 (en) * 2010-04-30 2011-11-03 Kinentia Biosciences Llc 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
KR101102335B1 (ko) * 2011-09-06 2012-01-03 (주)칠칠공사 수영 연습용 가변형 풀
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
JP6716582B2 (ja) 2014-11-07 2020-07-01 サブリミティ・セラピューティクス・リミテッドＳｕｂｌｉｍｉｔｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ シクロスポリンを含む組成物
CN115389659B (zh) * 2022-08-23 2024-07-16 浙江中医药大学 一种细胞膜键合磁性碳球复合材料及其制备方法和应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80449C (https=)
GB1003292A (en) 1960-12-08 1965-09-02 Sandoz Ag Improvements in or relating to 4-azathiaxanthene derivatives
NL132137C (https=) * 1963-04-24
FR145F (https=) 1964-06-01
CH421138A (de) 1965-11-04 1966-09-30 Wander Ag Dr A Verfahren zur Herstellung von Thioxanthenderivaten
US3409621A (en) 1966-04-01 1968-11-05 Schering Corp Piperazino-aza-dibenzo-[a, d]-cycloheptenes
US3625974A (en) 1967-04-28 1971-12-07 Fujisawa Pharmaceutical Co Dibenzothiazepine derivatives
NL6905642A (https=) 1968-04-12 1969-10-14
DE2163657A1 (de) 1970-12-22 1972-07-13 Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan) N-substituierte Piperidinverbindungen
GB1330966A (en) 1970-12-22 1973-09-19 Yoshitomi Pharmaceutical N-substituted piperidine compounds methods for their production and pharmaceutical compositions containing them
CA1010870A (en) 1972-12-08 1977-05-24 Niels Lassen Thiaxanthene derivative and method
US4250176A (en) 1976-12-21 1981-02-10 Janssen Pharmaceutica N.V. Piperazine derivatives
US4335122A (en) 1981-03-18 1982-06-15 Hoechst-Roussel Pharmaceuticals Inc. Dihydro-dibenzoxepines-thiepines and -morphanthridones, compositions and use
DE3326641A1 (de) 1982-07-27 1984-02-02 Basf Ag, 6700 Ludwigshafen 5,6-dihydro-11-h-morphantridin-6-one, ihre herstellung und diese enthaltende arzneimittel
US4547496A (en) 1983-06-24 1985-10-15 Kyowa Hakko Kogyo Co., Ltd. Antiulcer [1] benzepino[3,4-b]pyridine and compositions
DE3402060A1 (de) 1984-01-21 1985-08-01 Dr. Karl Thomae Gmbh, 7950 Biberach Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH0665664B2 (ja) 1985-01-18 1994-08-24 大塚製薬株式会社 モルフアントリジン誘導体
SE8500273D0 (sv) 1985-01-22 1985-01-22 Leo Ab Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder
JPS6310784A (ja) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
AU604726B2 (en) * 1986-06-26 1991-01-03 Kyowa Hakko Kogyo Co. Ltd. Antiarrhythmic agent
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
IT8721978A0 (it) 1987-09-21 1987-09-21 Angeli Inst Spa Nuovi derivati ammidinici triciclici.
US4882351A (en) 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
AU612437B2 (en) 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
WO1989010369A1 (en) 1988-04-28 1989-11-02 Schering Corporation Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use
US5242931A (en) 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
US4999363A (en) 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
DE3838912A1 (de) 1988-11-17 1990-05-23 Thomae Gmbh Dr K Mittel zur behandlung von akuten und chronischen obstruktiven atemwegserkrankungen
JPH0694464B2 (ja) 1991-01-23 1994-11-24 協和醗酵工業株式会社 三環式化合物およびその中間体
EP0511477B1 (en) 1991-03-11 1996-07-10 Kyowa Hakko Kogyo Co., Ltd. Indole derivatives
WO1992016226A1 (en) 1991-03-19 1992-10-01 Smithkline Beecham Corporation Il-1 inhibitors
WO1992020681A1 (en) 1991-05-23 1992-11-26 Schering Corporation Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
EP0524784A1 (en) 1991-07-23 1993-01-27 Schering Corporation Benzopyrido piperidylidene compounds as PAF antagonists
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US5679703A (en) 1992-09-16 1997-10-21 Kyowa Hakko Kogyo, Co., Ltd. Tricyclic compounds having ACAT inhibiting activity
US5538986A (en) 1993-12-06 1996-07-23 Schering Corporation Tricyclic derivatives, compositions and methods of use
MY113463A (en) 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
AU5271096A (en) 1995-04-07 1996-10-23 Novo Nordisk A/S Novel heterocyclic compounds
UA54385C2 (uk) 1995-04-07 2003-03-17 Ново Нордіск А/С N-заміщені азагетероциклічні карбонові кислоти та їх ефіри, спосіб їх одержання, фармацевтична композиція та спосіб лікування
US5801175A (en) 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
AU5270796A (en) 1995-04-07 1996-10-23 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters th ereof
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
JPH0940662A (ja) 1995-05-24 1997-02-10 Kyowa Hakko Kogyo Co Ltd 三環式化合物
EP0974583B1 (en) 1995-09-13 2002-05-29 Kyowa Hakko Kogyo Co., Ltd. Phenylpiperidine derivatives
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
US6686353B1 (en) 1996-05-20 2004-02-03 Teijin Intellectual Property Center Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6323206B1 (en) 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP0916668A4 (en) 1996-07-29 2000-08-16 Banyu Pharma Co Ltd CHEMOKIN RECEPTOR ANTAGONISTS
AU4801197A (en) 1996-09-13 1998-04-02 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibit ors
CN1237176A (zh) 1996-09-13 1999-12-01 先灵公司 用作fpt抑制剂的三环化合物
BR9712819A (pt) 1996-09-13 1999-11-23 Schering Corp Compostos tricìclicos úteis para inibição de função de proteìna g e para tratamento de doenças proliferativas
SK33099A3 (en) 1996-09-13 2000-05-16 Schering Corp Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
ES2235252T3 (es) 1996-09-13 2005-07-01 Schering Corporation Inhibidores triciclicos de la farnesil proteina transferasa.
ATE294172T1 (de) 1996-09-13 2005-05-15 Schering Corp Substituierte benzocycloheptapyridine derivate verwendbar als farnesyl-protein transferase inhibitoren
JP2001500508A (ja) 1996-09-13 2001-01-16 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼの阻害に有用な置換ベンゾシクロヘプタピリジン誘導体
CZ114199A3 (cs) 1996-10-04 1999-09-15 Novo Nordisk A/S N-Substituované azaheterocyklické sloučeniny
AU5604998A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998027815A1 (en) 1996-12-20 1998-07-02 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
WO1998043638A1 (en) 1997-03-27 1998-10-08 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for autoimmune diseases
HUP0002461A3 (en) 1997-04-15 2003-01-28 Kyowa Hakko Kogyo Kk Tricyclic benzothiepin a benzoxepin derivatives and pharmaceutical compositions thereof
US5877177A (en) 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6040318A (en) 1997-06-25 2000-03-21 Novo Nordisk A/S Tricycle substituted with azaheterocyclic carboxylic acids
US6048856A (en) 1997-12-17 2000-04-11 Novo Nordisk A/S Heterocyclic compounds
CA2318088A1 (en) 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
AU2331999A (en) 1998-01-21 1999-08-09 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
US6613905B1 (en) * 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO2000014089A1 (en) 1998-09-04 2000-03-16 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor

Also Published As

Publication number Publication date
US6509346B2 (en) 2003-01-21
CN1471536A (zh) 2004-01-28
IL147852A0 (en) 2002-08-14
HUP0202202A2 (hu) 2002-11-28
ES2321798T3 (es) 2009-06-12
DE60041336D1 (de) 2009-02-26
EA200200194A1 (ru) 2002-08-29
HK1044333A1 (zh) 2002-10-18
CA2391267A1 (en) 2001-02-08
JP2003506377A (ja) 2003-02-18
KR20020016926A (ko) 2002-03-06
EP1204665A2 (en) 2002-05-15
EP1204665B1 (en) 2009-01-07
AU6391400A (en) 2001-02-19
US20020119973A1 (en) 2002-08-29
WO2001009138A2 (en) 2001-02-08
JP4903333B2 (ja) 2012-03-28
ATE420090T1 (de) 2009-01-15
US20030045516A1 (en) 2003-03-06
WO2001009138A3 (en) 2001-09-13
MXPA02000978A (es) 2002-08-12
HUP0202202A3 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
BR0013065A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
BR0014179A (pt) Modernos derivados de ácido aminodicarboxìlico com propriedades farmacêuticas
BR9408378A (pt) Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos
KR890003369A (ko) 약제학적 제제
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR0014525A (pt) Processo de tratamento de distúrbios metabólicos, especialmente diabetes, ou uma doença ou condição associada com diabetes
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
ATE194987T1 (de) Substituierte dibenzoxazepinverbindungen, pharmazeutische zusammensetzungen und anwendungsmethoden
BRPI0405657A (pt) Método para o tratamento de insuficiência cardìaca grave e medicamento para o mesmo
ES2153906T3 (es) Uso de incienso para el tratamiento de la enfermedad de alzheimer.
PT920865E (pt) Utilizacao de ""norastemizole"" para o tratamento de disturbios alergicos
RU94044454A (ru) Ингибитор аутоимунных заболеваний
KR970025615A (ko) 암 전이 억제제
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
MXPA04004826A (es) Antagonista del receptor de quimioquinas y metodos para su uso.
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
KR960028907A (ko) 암환자를 치료하기 위한 세트랄린의 용도

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]